Serum samples from patients receiving intravenous streptokinase were examined for evidence of interaction in vivo between streptokinase and lactate dehydrogenase (EC 1.1 .1.27; LD). We found that this treatment produced a band of LD activity that remained at the electrophoretic origin of LD isoenzyme analysis. Treatment with tissue plasminogen activator produced no such band. The streptokinase-LD camplex could be removed from serum by ultracentrifugation. It remained in the circulation for as long as 48 h after streptokinase infusion. A similar phenomenon was observed in a case of pneumococcal sepsis. Examination of supemates from broth cultures of several species of Gram-positive cocci revealed interactions between human LD and Streptococcus groups A and C and also Streptococcus pneumoniae. Evidently streptokinase can form complexes with LD in vivo after either streptokinase therapy or infection, with consequent alteration of the LD isoenzyme pattern.
Serum samples from patients receiving intravenous streptokinase were examined for evidence of interaction in vivo between streptokinase and lactate dehydrogenase (EC 1.1 .1.27; LD). We found that this treatment produced a band of LD activity that remained at the electrophoretic origin of LD isoenzyme analysis. Treatment with tissue plasminogen activator produced no such band. The streptokinase-LD camplex could be removed from serum by ultracentrifugation. It remained in the circulation for as long as 48 h after streptokinase infusion. A similar phenomenon was observed in a case of pneumococcal sepsis. Examination of supemates from broth cultures of several species of Gram-positive cocci revealed interactions between human LD and Streptococcus groups A and C and also Streptococcus pneumoniae. Evidently streptokinase can form complexes with LD in vivo after either streptokinase therapy or infection, with consequent alteration of the LD isoenzyme pattern.
We previously found that lactate dehydrogenase (Llactate:NAD oxidoreductase, LD, EC 1.1.1.27) isoenzyme subunit M binds to the thrombolytic agent streptokinase in vitro, presumably because of a structural similarity between LD and plasminogen (1). Formation of complexes between streptokinase and LD in serum typically produces a band (precipitate) of LD activity that remains at the origin in LD isoenzyme electrophoresis.
Intravenous administration of thrombolytic agents such as streptokinase is now standard medical practice for early treatment of acute myocardial infarction (2). However, it is during this early phase of infarction and in subsequent hours that LD isoenzyme analysis is often used to assist in the clinical diagnosis of myocardial injury (3).
Here we present evidence for the in viva formation of complexes between LD arid streptokinase in patients treated with streptokinase. We also report a case of pneumococcal septicemia in which a similar LD electrophoretic anomaly appeared, directly attributable to a bacterial product from that infection. Finally, we have evaluated several bacterial species for production of streptokinase-like substances capable of binding to human LD, which potentially could do so in natural infections. These findings may have further significance in explaining the development of autoantibodies directed against LD.
Materials and Methods
Samples. Blood was sampled into evacuated collection tubes from individuals receiving thrombolytic therapy for acute myocardial infarction. Those patients were treated intravenously with either 1.5 mega-int. units of streptoki- 
Results

Effect of Streptokinase
Streptokinase-induced band of LD precipitate. Multiple serum samples were studied from four patients who received streptokinase within 5 h after initial onset of the chest pain of acute myocardial infarction.
Serum was also available from three of these four patients before the onset of symptoms; all showed normal LD isoenzyme distribution (e.g., Figure la) . A total of 27 samples were collected within 48 h after streptokunase infusion. LD isoenzyme electrophoresis of 16 of these samples showed either a smear of LD activity between LD2 and LD3 (four samples) or a precipitated band of LD activity remaining at the electrophoretic origin (12 samples) (Figure lb) . The normal band for beta-lipoprotein in serum migrated cathodally to the streptokinase-associated LD precipitate (Figure lb) . These samples also showed "ifipped" patterns (LD1 >LD2) in addition to the early increase of LD1 and LD2 activities characteristic of successful reperfusion of ischemic myocardium.
Serum samples were also obtained from four other patients, who received WA instead of streptokinase for treatment of acute myocardial infarction. Of 12 such samples collected within 48 h after WA infusion, none demonstrated smears or precipitated bands of LD activity on isoenzyme electrophoresis. All serum samples that demonstrated the bands and smears of LD associated with streptokinase administration had been separated from blood clots by centrifugation at about 5000 x g. Subsequent centrifugation at 165 000 x g for 1 h removed the LD precipitate from serum while retaining the same pattern of the other LD isoenzymes (Figure 1, c and d ). This finding indicated that the LD precipitate consisted of high-molecular-mass species.
To explore the size of these complexes further, we performed gel filtration by column chromatography on a mixture of nine volumes of serum plus one volume of streptokinase solution (final concentration 15 mega-int. units/L), applying 1 mL of this mixture to a Sepharose CL-2B column as described above. The column was eluted with phosphate-buffered saline, and 1-mL fractions were collected at a flow rate of 25 mLfh. Electrophoresis of each fraction showed that the LD-streptokinase complexes were eluted from the column near the void volume, in fraction 12, whereas the normally migrating LD isoenzymes were eluted in fractions 26 through 32. This result indicated that the complexes had a very high molecular size, greater than the upper limit for fractionation by Sepharose CL-2B (i.e., >4 x iO Da).
Serial patterns of LD isoenzymes after streptokinase infusion. During the 48 h after receiving streptokinase, all four patients initially showed a smear or extra band of LD. The aberrantly migrating LD activity then was absent for several hours, but recurred later, as depicted in Figure 2 
Effect of Infection
LD isoenzyme pattern in pneumococcal septicemia. A 74-year-old man had severe pneumonia, with Streptococcus pneumoniae being cultured from both sputum and blood. Because he had chest pains, we performed cardiac isoenzyme analysis. By these procedures and electrocardiogram, myocardial infarction was ruled out. The patient demonstrated a band ofLD activity at the origin and near absence of LD4 and LD5, although LD isoenzymes 1, 2, and 3 were quite intense compared with a normal pattern (cf Figure 3,  a and b) . Supernatant liquid from broth culture of this S. pneumoniae isolate was mixed in equal volumes with normal serum containing all LD isoenzymes. This mixture yielded a pattern of LD isoenzymes (Figure 3c ) similar to that of the patient's serum, with a band of LD activity remaining at the origin and near absence of the LD isoenzymes rich in M-subunits. Mixing sterile culture medium with human serum did not have this effect ( Figure  3d) , and the bacterial supernate alone contained no LD activity ( Figure 3e ). This suggests that a pneumococcal product also binds to human LD and in fact can do so in vivo during severe infection.
Interactions
of LD with products
from Gram-positive cocci. To investigate further the spectrum of bacteria that synthesize substances capable of binding to human LD, we examined several species of Gram-positive cocci obtained as clinical isolates from human infections. These bacteria were propagated on blood-agar plates before suspension culture in tryptic soy broth. None of the bacterial culture supernates had LD activity detectable by LI) isoenzyme electrophoresis. However, supernates from cultures of Streptococcus group A, Streptococcus group C, and S. pneurnoniae contained substances that bound to human LD, with group C producing the greatest amount of binding activity (Figure 4) . There was no detectable interaction under these conditions with supernates from Staphylococcus aureus, Staphylococcus epidermidis, or groups B, D, and F of Streptococcus.
Discussion
We have previously shown (1) by in vitro mixing experiments that streptokinase binds to LD isoenzyme subunit M, which shares a small region of homology with the site on plasminogen to which streptokinase is known to bind. The The search for direct interaction between LD and streptokinase was motivated by the observation that some patients treated for acute myocardial infarction with streptokinase subsequently developed autoantibodies against LD within weeks (4, 5). We have hypothesized that the complex of LD with the bacterial antigen streptokinase may stimulate a patient's immune system to produce these autoantibodies and perhaps other as-yet-unrecognized ones as well.
Our object was to look for direct evidence of interactions between LD and streptokinase in the circulation of patients exposed to streptokinase, either through therapeutic administration of that agent or through natural infections with bacteria capable of producing streptokinase or similar substances. We have consistently identified smears and an extra band of LD activity characteristic of LD-streptokinase interactions in the serum of patients who had recently received infusions of streptokinase for acute myocardial infarction. Smears of LD activity or extra bands of LD in the presence of streptokinase represent the same binding phenomenon, but with different concentrations of streptokinase or LD isoenzymes containing M subunits. These aberrant forms of LD were not detected in the serum of patients who received thrombolytic treatment with TPA. This LD.-streptokinase complex probably has a high molecular mass (>4 x iO Da), and therefore it does not migrate in an agarose electrophoresis gel optimized for the separation of uncomplexed LD isoenzymes.
One unexpected finding was that these complexes do not simply increase and then decline after streptokinase infusion, but rather can appear, disappear, and then reappear in a patient after a single large dose of streptokinase. These kinetics suggest sequestration either of streptokinase or of complexes, with subsequent release into the circulation. Although the presence or absence of the LD-streptokinase complex or its intensity in patients' samples could be a function of specimen processing (e.g., clot formation, centrifl.igation, storage), it is not likely, because very vigorous centrifligation was necessary to remove the complexes from serum (Figure ld) . Alternatively, after initial complex formation, there may be reassociation of streptokinase and LD molecules in the circulation or even between deposits of the complexes in tissue and the circulation.
It should be expected that virtually all patients receiving strepthkinase infusions will demonstrate atypical smears or bands ofLD activity at some time within the first 48 h of treatment.
Correct identification of these atypical forms may be useful in excluding the diagnosis of LD autoantibodies (which can show similar patterns) or even suspected technical error in performing the analysis. There may also be selective depletion of the LD isoenzymes rich in Msubunits owing to the participation of those isoenzymes in the complexes that precipitate at the electrophoretic origin. LD2 and LD3 appear to be less affected by streptokinase than do LD4 and LD5 (Figures 3 and 4) probably because LD4 and LD5 exhibit multiple streptokinase-binding sites (on the M-subunits) that allow them to participate in extensive matrices of complexes with divalent streptokinase molecules. Thus streptokinase infusion for treatment ofacute myocardial infarction may diminish the concentration of LD5 in the circulation, which has been used to predict passive congestion of the liver secondary to cardiac infarction and failure (6, 7). This clinical finding, which signals a poorer prognosis after myocardial infarction, might be missed in the diagnosis, owing to interaction of streptokinase with LD5. In addition, other diagnostic information deriving from the ratio of LD1 to the other LD isoenzymes in myocardial infarction (8) may also be altered by streptokinase binding. It does not appear from this study that thrombolytic therapy with TPA is likely to alter the LD isoenzyme patterns by direct binding. In addition to the occurrence of LD-streptokinase cornplexes in therapeutic administration, it is also very likely that streptococcal infections can lead to concentrations of streptokinase in the circulation sufficient to alter the electrophoretogram of LD isoenzymes, as seen in our patient with S. pneumoniae septicernia. Our survey of streptococcal isolates showed that groups A and C had products that reacted with U). These findings are consistent with early work that established that synthesis of streptokinase is restricted to groups A, C, and G as determined by fibrinolytic assay (9) .
This study has shown that, with standard clinical thrumbolytic protocols, there is opportunity for complexes between LD and the highly immunogenic streptokinase to form routinely in the circulation. These complexes should be available for processing by phagocytic cells of the immune system in such a way as to stimulate anti-U) antibody production in some patients after intravenous administration of streptokinase. On the other hand, most streptococcal infections of humans probably occur at skin or mucosal surfaces without causing bacteremia. In this regard, it may be noteworthy that a large proportion of anti-LD antibodies cited in the literature have been imniunoglobulin A (4, [10] [11] [12] [13] [14] [15] [16] [17] , whereas other autoantibodies generally are immunoglobulins G or M. This discrepancy may be explained if the original immunogenic stimulus to induction of an anti-LD is at a mucosal surface where the humoral immune response is primarily immunoglobulin A. Therefore, the interaction of streptokinase and like substances with LD at those surfaces may be the initiating event in many of the naturally occurring anti-U) antibodies for which there is no history of streptococcal sepsis or of streptokinase infusion.
Whatever the actual route of immune stimulation with streptokinase may be, this report has established that complexes between U) and streptokinase do occur in vivo and are easily recognized on electrophoresis. It also leads us to suggest that the current therapeutic use of streptokinase may lead to increased numbers of anti-LD autoantibodies in the future.
